Emmes, part of Emmes Group, announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials &nbs...
Eli Lilly and Company (NYSE: LLY), a global leader in biopharmaceuticals, has announced plans to expand its research and development (R&D) center in ...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...
The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...
Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, announces that the U...
BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and comme...
CPC (Colder Products Company), part of Dover and a leading manufacturer of connection technologies used in biopharmaceutical processing, today...
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...
Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) today announced positive results from the VLA15-221 Phase 2 study of t...
Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary...
HUTCHMED announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination w...
© 2025 Biopharma Boardroom. All Rights Reserved.
